Caring for Every Patient
Accunea understands the fundamentals of evidence-based practice and the decisions behind adopting a breakthrough device
SHOULD I USE THIS ORGAN?
The decision to transplant an organ or to discard it is one of the hardest a surgeon can make, particularly with the growing number of organs from older donors and those with comorbidities.
Discard rates average 15-20%, and rise with KDPI (36% 80-90, 63% 91-100)[1]. However, over-caution may be preventing thousands of dialysis-dependent patients from returning to a normal life[2], and condemning hundreds more to death each year.
Pre-transplantation biopsies, where performed, can provide additional reassurance over organ condition and likely final function, particularly from high risk donors[3]. But biopsy is not without controversy[4], and decisions regarding single or dual transplant remain difficult.
​
Accunea now provides clinicians with direct objective functional and metabolic measurements to suit a wide range of clinical practice - from hypothermic storage to normothermic reperfusion methodologies. With this evidence to hand, clinicians will find the hard decisions easier to make.
​
[1] Tanriover B, Mohan S, Cohen DJ, et al. Am J Transplant. 2014;14:404–15.
[2] Hosgood SA, Thomson E, Moore T, et al. Br J Surg 2017; 104(Suppl 3): 23
[3] Gandolfini I, Buzio C, Zanelli P, et al. Am J Transplant. 2014 Nov; 14(11): 2515–2525.
[4] Grifasi C, D'Alessandro V, D'Armiento M, et al. BMC Nephrol. 2014; 15: 207.
IS MY PATIENT RECOVERING NORMALLY?
Every transplant patient deserves an uncomplicated recovery, with the continuous smooth return to normal organ function. Unfortunately, many published Kaplan-Meier curves tell a different story - that the greatest rate of graft loss occurs in the first 30 days, affecting up to 6% of all transplants[1].
Current evidence shows that the time course of early changes in blood creatinine reflect long-term patient outcomes[2]. Mathematical models of this dynamic state can predict dialysis requirements and likely recovery of function[3]. This information helps not only with short-term dialysis decisions, but longer term outpatient monitoring.
​
Tissue glucose/lactate ratios have long been understood to reflect metabolic condition. This has been similarly demonstrated in porcine models of machine perfusion[4], a model immediately translatable to post-operative recovery.
​
Accunea now provides clinicians with continuous functional and metabolic indicators at the bedside to ensure an uneventful recovery, and allow for the tailoring of important drug dosages based upon real-time GFR. In addition, intelligent data pooling from multiple patient recoveries provides early warnings and notifications of likely deviations requiring intervention.
​
[1] Hamed MO, Chen Y, Pasea L, et al. Am J Transplant 2015; 15(6): 1632-1643
[2] Krogstrup NV, Bibby BM, Aulbjerg C, et al. Scand J Clin Lab Invest 2016; 76(4):319-323
[3] Pianta TJ, Endre ZH, Pickering JW, et al. PLoS ONE 2014; 10(5):e0125669
[4] Gowers SAN, Hamaoui K, Vallant N, et al. Analytical Methods 2018; 10:5273-5281
​
​
Trusted Results
Accunea uses biomarkers and diagnostic techniques supported by decades of clinical and laboratory validation
Needle-Free
Designed to interface with any standard cannula
Renal Function
Sensitive real-time clearance and GFR trends
Bloodless
Continuous sampling without damage or erythrocytes
Metabolic Markers
Proven clinical biomarkers for metabolic insights
Lab-on-Chip
Microfluidic technology for precise in-situ analysis
Calculators
Integrated dosage calculators for renally-cleared drugs